Cooperative CAR T cell therapy for AML patients
Official title: Project 4: Cooperative CAR T cell therapy in AML patients
Funded at Sloan-Kettering Inst Can Research · NIH-11265374 · Data updated 2026-11-12
A new CAR T cell approach uses two receptors together to target acute myeloid leukemia while aiming to limit damage to normal blood cells in adults.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 24, 2021 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $410,938 |
| NIH project number | 2P50CA254838-06 |
| Project ID | NIH-11265374 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with acute myeloid leukemia who are eligible for experimental CAR T cell therapy and meet specific safety criteria.
✕Less likely to help
Patients whose disease biology or health status makes CAR T therapy unsuitable or unsafe may not benefit.
What this research studies
This grant describes a two-receptor CAR T cell design called ADCLEC.syn1 that co-engages an ADGRE2-targeted CAR and a CLEC12A-targeted costimulator to better kill AML cells. The approach addresses the heterogeneity of AML antigens and the risk of leukemia cells escaping treatment by changing which antigens they express. By pairing receptors and calibrating their signaling, the strategy seeks to improve safety for patients while enhancing efficacy against AML. The project is conducted at Sloan Kettering and led by Dr. Jae Park, with a focus on translating this cooperative design into clinically applicable therapy.
Why it matters
Potential benefit: If successful, this strategy could provide a more effective and safer CAR T therapy for AML patients, potentially reducing relapse and improving survival.
How similar studies have gone: Preclinical and early clinical data in CAR T therapies for AML show promise, but antigen heterogeneity remains a challenge, making this approach novel.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Park, Jae — Sloan-Kettering Inst Can Research
- Study coordinator: Park, Jae
Related research
Other NIH-funded projects on the same topics.
-
SynthNode: A new, easier way to make CAR T cells for better cancer treatment
A new implantable device called SynthNode could simplify and lower the cost of CAR T cell therapy, helping patients with lymphoma, myeloma, and potentially solid tumors or lupus.
-
Intraperitoneal CAR T cells for peritoneal mesothelioma
A new approach uses CAR T cells delivered directly into the abdominal cavity to target mesothelioma, aiming to help people whose disease is confined to the abdomen.
-
Photobiomodulation to Boost CAR-T Cell Therapy for B-Cell Cancers
A patient-facing overview of using light-based therapy to improve CAR-T cell treatment for B-cell cancers, aiming for better effectiveness and lower costs.
-
Targeting death receptors to boost MET-CAR T cells for glioblastoma
Aims to make MET-CAR T cells work better against glioblastoma by using radiation to trigger death receptors on tumor cells.
-
CTO1681: reducing dangerous immune reactions in patients getting CAR T-cell therapy
A new oral drug (CTO1681) aims to prevent and lessen cytokine release syndrome in patients with blood cancers treated with CAR T-cell therapy.
-
CD2-targeted CAR-T therapy for T-cell lymphoma in a multi-center program
A patient-focused overview of a research grant that aims to improve CAR-T cell therapy for T-cell lymphoma by exploring CD2 as a new target and enhancing allogeneic CAR-T safety features.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.